NASDAQ:RVLP RVL Pharmaceuticals (RVLP) Stock Forecast, Price & News $0.85 +0.02 (+1.84%) (As of 05:11 PM ET) Add Compare Share Share Today's Range$0.81▼$0.8750-Day Range$0.77▼$1.1752-Week Range$0.72▼$2.99Volume32,340 shsAverage Volume58,078 shsMarket Capitalization$84.24 millionP/E RatioN/ADividend YieldN/APrice Target$2.83 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media RVL Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside234.2% Upside$2.83 Price TargetShort InterestHealthy0.14% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.24Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.39) to ($0.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.10 out of 5 starsMedical Sector352nd out of 981 stocksPharmaceutical Preparations Industry163rd out of 475 stocks 3.3 Analyst's Opinion Consensus RatingRVL Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.83, RVL Pharmaceuticals has a forecasted upside of 234.2% from its current price of $0.85.Amount of Analyst CoverageRVL Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.14% of the float of RVL Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRVL Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RVL Pharmaceuticals has recently decreased by 24.74%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRVL Pharmaceuticals does not currently pay a dividend.Dividend GrowthRVL Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RVLP. Previous Next 1.0 News and Social Media Coverage News SentimentRVL Pharmaceuticals has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for RVL Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for RVLP on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added RVL Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, RVL Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.30% of the stock of RVL Pharmaceuticals is held by insiders.Percentage Held by Institutions62.91% of the stock of RVL Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for RVL Pharmaceuticals are expected to grow in the coming year, from ($0.39) to ($0.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RVL Pharmaceuticals is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RVL Pharmaceuticals is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRVL Pharmaceuticals has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About RVL Pharmaceuticals (NASDAQ:RVLP) StockRVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.Read More Receive RVLP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RVL Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RVLP Stock News HeadlinesJune 5, 2023 | americanbankingnews.comComparing Bio-Path (NASDAQ:BPTH) and RVL Pharmaceuticals (NASDAQ:RVLP)June 2, 2023 | finance.yahoo.comShareholders in RVL Pharmaceuticals (NASDAQ:RVLP) are in the red if they invested three years agoJune 8, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 17, 2023 | americanbankingnews.comEquities Analysts Set Expectations for RVL Pharmaceuticals plc's Q4 2023 Earnings (NASDAQ:RVLP)May 16, 2023 | americanbankingnews.comFY2027 EPS Estimates for RVL Pharmaceuticals plc Decreased by HC Wainwright (NASDAQ:RVLP)May 16, 2023 | americanbankingnews.comRVL Pharmaceuticals (NASDAQ:RVLP) Price Target Cut to $4.00May 13, 2023 | finance.yahoo.comTime To Worry? Analysts Just Downgraded Their RVL Pharmaceuticals plc (NASDAQ:RVLP) OutlookMay 12, 2023 | finance.yahoo.comRVLP: First Quarter ResultsJune 8, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 12, 2023 | msn.comRVL Pharmaceuticals: Q1 Earnings InsightsMay 12, 2023 | finance.yahoo.comQ1 2023 RVL Pharmaceuticals PLC Earnings CallMay 11, 2023 | americanbankingnews.comShort Interest in RVL Pharmaceuticals plc (NASDAQ:RVLP) Declines By 34.8%May 10, 2023 | msn.comEarnings Preview: RVL PharmaceuticalsMay 9, 2023 | americanbankingnews.comRVL Pharmaceuticals (RVLP) to Release Quarterly Earnings on ThursdayMay 2, 2023 | americanbankingnews.comRVL Pharmaceuticals (NASDAQ:RVLP) Price Target Cut to $2.00 by Analysts at BarclaysMay 1, 2023 | finance.yahoo.comRVLP: Selected for NewBeauty AwardMay 1, 2023 | markets.businessinsider.comBarclays Sticks to Their Buy Rating for RVL Pharmaceuticals (RVLP)April 26, 2023 | benzinga.comRVL Pharmaceuticals Stock (NASDAQ:RVLP), DividendsApril 22, 2023 | americanbankingnews.comContrasting RVL Pharmaceuticals (NASDAQ:RVLP) & Verona Pharma (NASDAQ:VRNA)April 17, 2023 | finance.yahoo.comInvestors Aren't Entirely Convinced By RVL Pharmaceuticals plc's (NASDAQ:RVLP) RevenuesApril 16, 2023 | americanbankingnews.comRVL Pharmaceuticals (NASDAQ:RVLP) Shares Down 4.3% April 9, 2023 | thestreet.comRVL Pharmaceuticals plcApril 4, 2023 | marketwatch.comRVL Pharmaceuticals Announces that Upneeq(R) Wins "Best Eye Drop for Drooping Lids" NewBeauty in 13th Annual Beauty AwardsApril 3, 2023 | finance.yahoo.comRVL Pharmaceuticals Announces that Upneeq® Wins “Best Eye Drop for Drooping Lids” NewBeauty in 13th Annual Beauty AwardsMarch 25, 2023 | americanbankingnews.comEquities Analysts Offer Predictions for RVL Pharmaceuticals plc's Q2 2023 Earnings (NASDAQ:RVLP)March 25, 2023 | americanbankingnews.comCantor Fitzgerald Research Analysts Boost Earnings Estimates for RVL Pharmaceuticals plc (NASDAQ:RVLP)March 25, 2023 | americanbankingnews.comRVL Pharmaceuticals plc (NASDAQ:RVLP) Expected to Earn Q1 2023 Earnings of ($0.11) Per ShareSee More Headlines RVLP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVLP Company Calendar Last Earnings3/20/2023Today6/08/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RVLP CUSIPN/A CIK1739426 Webwww.osmotica.com Phone(908) 809-1300FaxN/AEmployees156Year FoundedN/APrice Target and Rating Average Stock Price Forecast$2.83 High Stock Price Forecast$4.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+225.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,690,000.00 Net Margins-152.21% Pretax Margin-151.90% Return on Equity-111.27% Return on Assets-46.70% Debt Debt-to-Equity Ratio1.33 Current Ratio2.34 Quick Ratio2.32 Sales & Book Value Annual Sales$49.72 million Price / Sales1.74 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book1.71Miscellaneous Outstanding Shares99,350,000Free Float94,084,000Market Cap$86.43 million OptionableOptionable Beta1.21 Key ExecutivesBrian A. MarkisonChairman, Chief Executive & Financial OfficerJames SchaubChief Operating Officer & Executive Vice PresidentSergio AlegreVice President-Global ComplianceMichael J. DepetrisChief Accounting OfficerJarret MillerExecutive Vice President-Human ResourcesKey CompetitorsvTv TherapeuticsNASDAQ:VTVTApplied TherapeuticsNASDAQ:APLTDaré BioscienceNASDAQ:DARERelmada TherapeuticsNASDAQ:RLMDTiziana Life SciencesNASDAQ:TLSAView All CompetitorsInstitutional OwnershipTitleist Asset Management LLCBought 105,003 shares on 5/18/2023Ownership: 0.106%AIGH Capital Management LLCSold 545,471 shares on 5/15/2023Ownership: 1.265%Renaissance Technologies LLCSold 17,800 shares on 5/12/2023Ownership: 0.702%Scoggin Management LPBought 500,000 shares on 5/12/2023Ownership: 0.503%Dimensional Fund Advisors LPSold 23,487 shares on 5/12/2023Ownership: 0.073%View All Institutional Transactions RVLP Stock - Frequently Asked Questions Should I buy or sell RVL Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RVL Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVLP shares. View RVLP analyst ratings or view top-rated stocks. What is RVL Pharmaceuticals' stock price forecast for 2023? 3 analysts have issued 1 year target prices for RVL Pharmaceuticals' stock. Their RVLP share price forecasts range from $2.00 to $4.00. On average, they expect the company's stock price to reach $2.83 in the next twelve months. This suggests a possible upside of 225.7% from the stock's current price. View analysts price targets for RVLP or view top-rated stocks among Wall Street analysts. How have RVLP shares performed in 2023? RVL Pharmaceuticals' stock was trading at $1.12 at the beginning of 2023. Since then, RVLP shares have decreased by 22.3% and is now trading at $0.87. View the best growth stocks for 2023 here. Are investors shorting RVL Pharmaceuticals? RVL Pharmaceuticals saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 65,700 shares, a decline of 24.7% from the April 30th total of 87,300 shares. Based on an average daily trading volume, of 69,300 shares, the short-interest ratio is presently 0.9 days. Approximately 0.1% of the company's stock are short sold. View RVL Pharmaceuticals' Short Interest. When is RVL Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our RVLP earnings forecast. How were RVL Pharmaceuticals' earnings last quarter? RVL Pharmaceuticals plc (NASDAQ:RVLP) announced its quarterly earnings data on Monday, March, 20th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.03. The company had revenue of $9.81 million for the quarter, compared to the consensus estimate of $12.10 million. RVL Pharmaceuticals had a negative trailing twelve-month return on equity of 111.27% and a negative net margin of 152.21%. During the same period in the previous year, the business earned ($0.26) EPS. What is RVL Pharmaceuticals' stock symbol? RVL Pharmaceuticals trades on the NASDAQ under the ticker symbol "RVLP." Who are RVL Pharmaceuticals' major shareholders? RVL Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include AIGH Capital Management LLC (1.26%), Renaissance Technologies LLC (0.70%), Scoggin Management LP (0.50%), Titleist Asset Management LLC (0.11%), Insight Advisors LLC PA (0.08%) and Dimensional Fund Advisors LP (0.07%). How do I buy shares of RVL Pharmaceuticals? Shares of RVLP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is RVL Pharmaceuticals' stock price today? One share of RVLP stock can currently be purchased for approximately $0.87. How much money does RVL Pharmaceuticals make? RVL Pharmaceuticals (NASDAQ:RVLP) has a market capitalization of $86.43 million and generates $49.72 million in revenue each year. The company earns $-51,690,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis. How many employees does RVL Pharmaceuticals have? The company employs 156 workers across the globe. How can I contact RVL Pharmaceuticals? RVL Pharmaceuticals' mailing address is 400 Crossing Blvd, Bridgewater, New Jersey 08807-2863. The official website for the company is www.osmotica.com. The company can be reached via phone at (908) 809-1300 or via email at lwilson@insitecony.com. This page (NASDAQ:RVLP) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RVL Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.